Development and Evaluation of Lapatinib Solid Lipid Nanoparticles in the Management of Breast Cancer
Abstract
The current research was aimed at formulation of Lapatinib loaded solid lipid nanoparticles (SLNs) followed by evaluation for effective treatment of breast cancer. The formulations prepared by homogenization and ultrasonication and evaluated for zeta potential, particle size, polydispersity index, entrapment efficiency and in-vitro dissolution studies. Entrapment efficiency studies indicated proportional relation between concentration of lipid and the amount of drug entrapped. The physicochemical parameter evaluation data indicated 94.27% entrapment efficiency, 130 nm particle size and -19.9 zeta potential for stable formulation. The in vitro drug dissolution studies indicated that Lapatinib loaded SLNs (F6) formulated with Dynasan 116 and Egg Lecithin was suitable for anti-cancer therapy with higher drug dissolution rate.
Keywords:
Lapatinib, SLNs, Solubility, Breast cancer, Dynasan, Egg lecithin.DOI
https://doi.org/10.25004/IJPSDR.2019.110515References
Bargoni A, Cavalli R, Zara GP. Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II – Tissue distribution. Pharm Res. 2001; 43: 497–502.
Freitas C, Müller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticles (SLN) dispersions. Int. J. Pharm. 1998; 168:221–229.
Cavalli R, Caputo O, Gasco MR. Solid lipospheres of doxorubicin and idarubicin. Int J Pharm. 1993; 89:9-12.
Stuchlik M, Zak S. Lipid-based vehicle for oral drug delivery. Biomedical Papers of the Medical Faculty of the University Palacky. 2001; 145(2):17–26.
Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharm SciTech. 2011; 12(1):62–76.
Rusnak D, Affleck W, Cockerill K, Stubberfield SG, Harris C, Page R, Smith M, Guntrip KJ, Carter SB, Shaw MC. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer. Cancer Res. 2001; 61:7196–7203.
Konecny GE Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006; 66:1630–1639.
Higa GM, Abraham J. Lapatinib in the treatment of breast cancer. Expert Review of Anticancer Therapy (Future Drugs). 2007; 7(9): 1183–92.
Glaxo Smith Kline (GSK). Glaxo Smith Kline receives marketing authorization in the EU for Tyverb (lapatinib), the first oral targeted therapy for ErbB2-positive breast cancer. Glaxo Smith Kline (GSK) Press release. 2008; 06-12.
Venkateshwarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Rel. 2004; 95:627-38.
Dudhipala N, Veerabrahma K. Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: Pharmacokinetic and pharmacodynamic evaluation. European Journal of Pharmaceutics and Biopharmaceutics. 2017; 110:47–57.
Singh S, Dobhal AK, Jain A, Pandit JK, Chakraborty S. Formulation and evaluation of solid lipid nanoparticles of a water soluble drug: Zidovudine. Chemical and Pharmaceutical Bulletin. 2010; 58(5):650–655.
Fundaro A, Cavalli R, Bargoni A. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after IV administration to rats. Pharm Res. 2000; 42: 337–43.
Published
Abstract Display: 544 
PDF Downloads: 777 
